- Conditions
- Invasive Aspergillosis, Invasive Pulmonary Aspergillosis
- Interventions
- Investigational Agent: VL-2397, Standard treatment: Voriconazole, Isavuconazole, or Liposomal amphotericin B
- Drug
- Lead sponsor
- Vical
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 11
- States / cities
- Birmingham, Alabama • La Jolla, California • Sacramento, California + 8 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 169–192
of 5,545
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Photoaging
- Interventions
- Hexylresourcinol, Hydroquinone
- Other
- Lead sponsor
- Sytheon Ltd.
- Industry
- Eligibility
- 35 Years to 65 Years · Female only
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- Type 1 Diabetes
- Interventions
- 530G Insulin pump
- Device
- Lead sponsor
- Medtronic MiniMed, Inc.
- Industry
- Eligibility
- 2 Years to 15 Years
- Enrollment
- 194 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 16
- States / cities
- Los Angeles, California • Orange, California • Sacramento, California + 12 more
- Conditions
- Brain Edema, Brain Tumor
- Interventions
- hCRF, placebo hCRF
- Drug
- Lead sponsor
- Celtic Pharma Development Services
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2008
- U.S. locations
- 27
- States / cities
- Phoenix, Arizona • Fresno, California • Newport Beach, California + 22 more
- Conditions
- Prostate Cancer
- Interventions
- 3D-CRT
- Radiation
- Lead sponsor
- Radiation Therapy Oncology Group
- Network
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 1,084 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1994 – 2013
- U.S. locations
- 213
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 165 more
- Conditions
- Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Fallopian Tube Undifferentiated Carcinoma, Malignant Ovarian Brenner Tumor, Ovarian Clear Cell Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mucinous Adenocarcinoma, Ovarian Seromucinous Carcinoma, Ovarian Serous Adenocarcinoma, Ovarian Transitional Cell Carcinoma, Ovarian Undifferentiated Carcinoma, Primary Peritoneal Clear Cell Adenocarcinoma, Primary Peritoneal Endometrioid Adenocarcinoma, Primary Peritoneal Serous Adenocarcinoma, Primary Peritoneal Transitional Cell Carcinoma, Primary Peritoneal Undifferentiated Carcinoma, Stage II Fallopian Tube Cancer AJCC v6 and v7, Stage II Ovarian Cancer AJCC v6 and v7, Stage IIA Fallopian Tube Cancer AJCC v6 and v7, Stage IIA Ovarian Cancer AJCC V6 and v7, Stage IIB Fallopian Tube Cancer AJCC v6 and v7, Stage IIB Ovarian Cancer AJCC v6 and v7, Stage IIC Fallopian Tube Cancer AJCC v6 and v7, Stage IIC Ovarian Cancer AJCC v6 and v7, Stage III Ovarian Cancer AJCC v6 and v7, Stage III Primary Peritoneal Cancer AJCC v7, Stage IIIA Ovarian Cancer AJCC v6 and v7, Stage IIIA Primary Peritoneal Cancer AJCC v7, Stage IIIB Ovarian Cancer AJCC v6 and v7, Stage IIIB Primary Peritoneal Cancer AJCC v7, Stage IIIC Ovarian Cancer AJCC v6 and v7, Stage IIIC Primary Peritoneal Cancer AJCC v7, Stage IV Fallopian Tube Cancer AJCC v6 and v7, Stage IV Ovarian Cancer AJCC v6 and v7, Stage IV Primary Peritoneal Cancer AJCC v7
- Interventions
- Bevacizumab, Carboplatin, Cisplatin, Laboratory Biomarker Analysis, Paclitaxel, Quality-of-Life Assessment
- Biological · Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 1,560 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2016
- U.S. locations
- 503
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 332 more
- Conditions
- Fibrosis, Scarring, Scar, Wounds, Injuries, Keloid, Cicatrix, Hypertrophic
- Interventions
- LED-RL Phototherapy, Mock Therapy
- Device
- Lead sponsor
- Jared Jagdeo, MD, MS
- Federal
- Eligibility
- Not listed
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Mather, California
- Conditions
- Irritable Bowel Syndrome With Diarrhea (IBS-D)
- Interventions
- DNK333, Placebo
- Drug
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 18 Years to 65 Years · Female only
- Enrollment
- 180 participants
- Timeline
- 2006 – 2007
- U.S. locations
- 37
- States / cities
- Tucson, Arizona • North Little Rock, Arkansas • Los Angeles, California + 34 more
- Conditions
- Congenital Myasthenic Syndrome
- Interventions
- 3,4-Diaminopyridine
- Drug
- Lead sponsor
- Ricardo Maselli
- Other
- Eligibility
- 3 Months to 75 Years
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- Cardiogenic Shock, Acute Myocardial Infarction, STEMI - ST Elevation Myocardial Infarction, NSTEMI - Non-ST Segment Elevation MI, Heart Attack
- Interventions
- Not listed
- Lead sponsor
- Henry Ford Health System
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 406 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 75
- States / cities
- Birmingham, Alabama • Fayetteville, Arkansas • Little Rock, Arkansas + 61 more
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Aclidinium bromide, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 561 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009
- U.S. locations
- 104
- States / cities
- Birmingham, Alabama • Jasper, Alabama • Mobile, Alabama + 90 more
- Conditions
- Cystic Fibrosis
- Interventions
- AZLI 75 mg two times a day (BID)/three times a day (TID), Placebo two times a day (BID)/three times a day (TID)
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 6 Years and older
- Enrollment
- 211 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2006
- U.S. locations
- 56
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • La Jolla, California + 50 more
- Conditions
- Primary Focal Hyperhidrosis, Axilla
- Interventions
- DTS-G2 System, DTS System (Sham treatment)
- Device
- Lead sponsor
- Miramar Labs
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 7
- States / cities
- Sacramento, California • San Diego, California • Sunnyvale, California + 4 more
- Conditions
- Muscular Dystrophy, Duchenne, Muscular Dystrophies, Muscular Disorders, Atrophic, Muscular Diseases, Musculoskeletal Diseases, Neuromuscular Diseases, Nervous System Diseases, Genetic Diseases, X-Linked, Genetic Diseases, Inborn
- Interventions
- Ataluren
- Drug
- Lead sponsor
- PTC Therapeutics
- Industry
- Eligibility
- 7 Years to 15 Years · Male only
- Enrollment
- 219 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 21
- States / cities
- Los Angeles, California • Sacramento, California • Stanford, California + 18 more
- Conditions
- Platinum-Sensitive Ovarian Cancer in First Relapse
- Interventions
- Farletuzumab, Placebo
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 332 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 35
- States / cities
- Phoenix, Arizona • Los Angeles, California • Orange, California + 32 more
- Conditions
- Knee Osteoarthritis
- Interventions
- Topical Diclofenac gel 1%
- Drug
- Lead sponsor
- University of California, Davis
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 220 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- HIV Infections
- Interventions
- Aldesleukin
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- Not listed
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 2006
- U.S. locations
- 10
- States / cities
- Los Angeles, California • Palo Alto, California • Sacramento, California + 6 more
- Conditions
- Recurrent Adult Hodgkin Lymphoma, Recurrent Childhood Hodgkin Lymphoma, Refractory Childhood Hodgkin Lymphoma
- Interventions
- Brentuximab Vedotin, Gemcitabine Hydrochloride
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 13 Months to 30 Years
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2021
- U.S. locations
- 109
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Downey, California + 91 more
- Conditions
- Hepatitis C Virus, Advanced Fibrosis, Cirrhosis
- Interventions
- PEG -Intron, Colchicine
- Drug
- Lead sponsor
- Beth Israel Deaconess Medical Center
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 549 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2010
- U.S. locations
- 49
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Bakersfield, California + 39 more
- Conditions
- Burns
- Interventions
- NovoSorb BTM, Standard of Care
- Device · Procedure
- Lead sponsor
- PolyNovo Biomaterials Pty Ltd.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 23
- States / cities
- Phoenix, Arizona • Los Angeles, California • Sacramento, California + 19 more
- Conditions
- Sickle Cell Disease
- Interventions
- Etavopivat Tablets Low dose, Etavopivat Tablets High dose, Placebo Tablets, Etavopivat Tablets
- Drug
- Lead sponsor
- Forma Therapeutics, Inc.
- Industry
- Eligibility
- 12 Years to 65 Years
- Enrollment
- 450 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 63
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 47 more
- Conditions
- Lung Cancer, Non-Small Cell
- Interventions
- GSK1572932A Antigen-Specific Cancer Immunotherapeutic, Placebo Control
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,278 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2014
- U.S. locations
- 201
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 157 more
- Conditions
- Fragile X Syndrome
- Interventions
- Low dose of MRM-3379, Middle Dose of MRM-3379, High dose of MRM-3379, Placebo, Low dose of MRM-3379 Open-Label
- Drug
- Lead sponsor
- Mirum Pharmaceuticals, Inc.
- Industry
- Eligibility
- 13 Years to 45 Years · Male only
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 15
- States / cities
- Phoenix, Arizona • Irvine, California • Orange, California + 12 more
- Conditions
- Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Stage IB Esophageal Cancer AJCC v7, Stage IIA Esophageal Cancer AJCC v7, Stage IIB Esophageal Cancer AJCC v7, Stage IIIA Esophageal Cancer AJCC v7, Stage IIIB Esophageal Cancer AJCC v7
- Interventions
- Carboplatin, Laboratory Biomarker Analysis, Paclitaxel, Quality-of-Life Assessment, Radiation Therapy, Therapeutic Conventional Surgery, Trastuzumab
- Drug · Other · Radiation + 2 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 203 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2023
- U.S. locations
- 634
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 407 more